A total of 276 sequential serum samples from 34 men with antibodies to the human immunodeficiency virus (HIV) followed up for two to seven years were analysed for HIV antigen and antibodies to the viral core and envelope proteins. Results were correlated with clinical outcome and CD4 T lymphocyte count. Both antigenaemia and the disappearance of antibodies to the core protein were associated with development of the acquired immune deficiency syndrome (AIDS) or AIDS related complex and depletion of CD4 cells. Thus AIDS or AIDS related complex developed in eight out of 16 patients with antigenaemia compared with one out of 18 patients without antigenaemia. Low counts of CD4 cells (<OU5x 109/l) were found in 14 of the 16 patients with antigenaemia and five of the 18 without antigenaemia. Nine patients seroconverted to HIV during the study; two of these developed antigenaemia 14 and 16 months after the estimated time of seroconversion.
Introduction
After acute infection with the human immuodeficiency virus (HIV) the viral core antigen p24 is detectable in serum.1-' When antibodies develop antigen often becomes undetectable. In the late stages of HIV infection an association between HIV antigenaemia and progression to overt HIV related disease has been reported.4 5 Though prospective studies on the occurrence of HIV specific antibodies and antigen have been performed during seroconversion with follow up for one year,' information on the temporal association between HIV antigen in serum, antibody profile, and the immunological and clinical state ofpatients during long term follow up is scarce. We report the findings in sequential serum samples from 34 men followed up for two to seven years with respect to the occurrence of HIV antigen and antibody profile and relate these to the immunological and clinical outcome.
Patients and methods
Sequential serum samples were studied from 34 men in whom HIV antibodies were detected before 31 December 1984. Three of the patients were haemophiliacs and the other 31 homosexuals.
From late 1984 serum samples were collected prospectively about every four months and before then about every six months for evaluation of the efficacy of factor VIII preparation, a prospective study of hepatitis B, and as part of screening for the acquired immune deficiency syndrome (AIDS).6 Altogether 276 samples were examined from the 34 patients (median 7 (range 5-14) from each patient). With the exception of generalised lymphadenopathy, which was present in 20 patients, none had symptoms at the time of the first serum sample. The study group was followed up for a median of 36 months (range 25-84). Clinical symptoms during follow up were graded according to the system used by the Centers for Disease Control for HIV infection.' AIDS related complex in this study includes patients in group IV, subgroups A, C-2, and E (one patient with poorly differentiated Hodgkin's lymphoma). None 567 568 immunoassay using human IgG of high antibody titre as both capture and indicator antibodies. Results were expressed as the optical density of the test well divided by the optical density of the control well (T:C ratio). Samples giving T:C ratios >2-0 were scored positive provided that the optical density of the test well was >0 1. Details of the method have been described8 (C M Nielsen, P Feorino, C Pedersen, B F Vestergaard, paper in preparation).
Antibodies to HIV envelope and core antigens were assayed by a commercially available competitive enzyme immunoassay (Abbott Laboratories) employing recombinant HIV antigens. The core antigen contains the entire p24gag gene product as well as part of the p15 and pl8gag gene products. The envelope antigen contains the entire p41env gene product as well as part of the gpl20env gene product.9 In this paper antibodies to the core antigens are designated anti-p24 and antibodies to the envelope antigens anti-p41.
T cell subsets were quantified by using monoclonal antibodies, as described.'0 Thus CD4 T lymphocytes were counted by using Leu3 antibodies.
Statistical analysis was by the Mann-Whitney rank sum test. Proportions were compared by the X2 test or Fisher's exact test. In the group of patients with antigenaemia the median antigen level (T:C ratio) was 5-5 (range 4-1-17-2) at the time of diagnosis in those with AIDS or AIDS related complex, as compared with 2-7 (range 2-1-5-4) at the end of follow up in those who remained asymptomatic (p<0-01). Once developed, antigenaemia persisted in all but two of the patients. One patient (case 15; see fig 1) had one negative sample after the appearance of antigenaemia; in this patient, however, both the positive and negative samples gave borderline T:C ratios. Another patient (case 14) became antigen negative after the diagnosis of AIDS and remained so until his death. Shortly before becoming antigen negative this patient had received cytotoxic treatment for metastatic Kaposi's sarcoma.
All 256 anti-HIV positive serum samples (ELISA) from the 34 patients were anti-p41 positive. By contrast, anti-p24 was undetectable or disappeared in 12 patients, 11 of whom were or became antigen positive. Loss of anti-p24 was significantly associated with the development of clinical disease and depletion of CD4 cells (table) . Figure 1 shows the combined results for HIV antigenaemia, antibody profile, CD4 count, and clinical outcome in the 16 antigen positive patients. The onset of AIDS and AIDS related complex was preceded by antigenaemia by a median of 24 (range 9-29) and 13 (0-27) months, respectively. Five patients had antigenaemia and detectable anti-p24 concomitantly. The median antigen level (T:C ratio) was 4 5 (range 2-1-33-0) in anti-p24 negative samples compared with 3-3 (2-1-6-6) in anti-p24 positive samples (p<0-01). The patient without detectable antigenaemia who developed AIDS was persistently anti-p24 positive.
In nine patients seroconversion occurred. The median interval between the last negative and first positive samples was nine months (range [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . -p24 positive  22  1  1  8  3  Anti-p24negative  12  5  2  11  8 Discussion This study shows that HIV antigenaemia and loss of antibody to the viral core protein are associated with the development of clinical disease in patients with HIV infection. Half the patients with antigenaemia developed AIDS or AIDS related complex and most of the remaining antigen positive subjects, though asymptomatic, had signs of immunodeficiency as judged by low counts of CD4 T lymphocytes. Our findings agree with those of others. Thus Kenny et al in a study of 32 patients with AIDS associated complex found progression to AIDS to be associated with HIV antigenaemia or anti-p24 negativity, or both,5 and a three year study by Weber et al showed a significant association of declining anti-p24 titre with progression of disease and, as in our study, that serological changes often preceded disease progression by more than 24 months." Weber et al did not test serum for HIV antigen.
From our data and other studies of acute'3 and chronic HIV infection45'2-5 the serological profile of HIV infection in most patients appears to be as shown in figure 2 . In a minority of patients, however, HIV antigen remains detectable after the primary infection' (Pedersen et al, unpublished) .
The serological events during acute infection resemble those of other viral infections associated with antigenaemia, but the recurrence of antigenaemia and loss of anti-p24 during late stages of the infection are less readily explained. Loss of anti-p24 due to defective B cell function is unlikely to be the initial event, as the production of antibodies directed against other HIV antigens remains intact. More probably loss of anti-p24 is secondary to the formation ofantigen-antibody complexes due to increasing amounts of antigen in the late stages of the infection. This hypothesis is supported by the finding of HIV antigen in polyethylene glycol precipitated immune complexes both in patients with anti-p24 and in patients without detectable anti-p24 in serum. '6 Our study shows that some patients develop antigenaemia within two years of infection while others remain healthy without antigenaemia for up to seven years. The reasons for the different courses remain obscure. Further studies of the serological profile in HIV infection, with special attention paid to events preceding antigenaemia and loss of anti-p24, may establish the role of possible cofactors for the progression of clinical disease.
Recurrence of HIV antigenaemia seems to indicate a poor prognosis. Kaplan-Meier curves (data not shown) show that 49% of patients will develop AIDS within two years from the reappearance of antigenaemia. This must be added to the long list of clinical, histological, immunological, and serological indicators of a bad prognosis."1 The ideal prognostic test must be simple to do and interpret. The antigen test fulfils these criteria and has the further advantage that it can be used in the form ofa filter paper test,8 which may be of value in developing countries.
